CClinicalTrials.gg
WithdrawnNCT04763837Updated Apr 29, 2022

Migration of Intraureteral Stents Compared to Conventional Double-J Stents.

An interventional study of Intraureteral stent and Conventional Double-J stent in Urologic Diseases and Urological System Complication of Procedure, sponsored by University of Louisville. Withdrawn. Open to participants aged 1 Year to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by University of Louisville · Not applicable, Interventional, and Treatment

Why this study was withdrawn
unable to continue
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
1 Year to 100 Years
Sex
All
01

Study summary

The purpose of this study is to determine if stents placed with only one loop in the kidney move more than stents placed with a loop in both the kidney and a bladder. Participants in this study will undergo placement of a stent into the ureter that drains urine from the kidney into the bladder. The stent will be placed in 1 of 2 ways: either with only a loop of the stent is left in the kidney or in the regular manner where a loop of the stent is left in both the kidney and in the bladder. The position of the stent will be measured at the time of placement. When the stent is removed, the position of the stent will be measured prior to pulling the stent.

Read the detailed description

The ureteral stent is one of the most extensively used tools in the field of urology. They are used for aiding post-operative healing of the ureter, visualizing the ureteral during procedures, and alleviating ureteral obstruction (eg. nephrolithiasis). Double-J stents, which are secured by loops in both the renal pelvis and the bladder, have become most urologists' go-to choice for ureteral stents since they were introduced in the 1970s. Unfortunately, it has been shown that 80-90% of patients with ureteral stents have urinary complaints following stent placement.

Interestingly, a recent study suggested utility of intraureteral stents. These stents have one loop in the renal pelvis while their distal end is positioned proximal to the ureteral orifice. The above-mentioned study showed that patients with intraureteral stents had less discomfort as opposed to the those that had double-J stents.

Due to the immense number of patients that require ureteral stent placement, this improvement in comfort is very promising for the urological field. However, no one has studied if stents placed intraureterally migrate from the time they are placed to the time they are removed. If stents migrate proximally toward the renal pelvis, it is possible that retrieval could be more difficult, and the ureteral patency established by the stent could be compromised.

The objective of this study is to determine if intraureterally placed stents migrate as compared to ureteral stents placed via the conventional method.

This study will be a prospective, randomized controlled, single-blinded trial. The subjects will include up to 140 patients (about 70 subjects per group) from ages 1-100 years old that are to undergo stent placement for nephrolithiasis, hydronephrosis, and urological cancer.

Prior to the procedure, each patient that has agreed to participate in this study will be randomly assigned to receive a stent placed intraureterally or a stent placed in the conventional manner. After each intraureteral stent is placed via cystoscopy, the distance of the distal end of the stent to the ureteral orifice will be measured via fluoroscopy that was calibrated prior to the procedure. After each double-J stent is placed via cystoscopy, the length of stent that is present in the bladder will also be measured using calibrated fluoroscopy . Subjects will not be informed of which group they are assigned to. When the patients return for stent removal, the previously mentioned distances will be measured again prior to pulling the stent. They will also be asked to complete the ureteral stent symptom questionnaire (USSQ) to assess stent-associated discomfort. The primary endpoint of the study would be stent migration distance (mm). Secondary endpoints would include patient comfort level.

All medical records will be accessed on secure devices and networks. All subjects will be assigned a subject number upon enrolled in the study. When a researcher needs to record data from a patient's medical records, they will record this information with the patient's corresponding subject number. Only the researchers involved in this study will have access to the document that includes patient identifiers and their subject number. At the conclusion of this study, the document with patient identifiers and subject numbers will be destroyed.

Data will be collected from electronic medical records of patients from ULP (University of Louisville Physicians) Urology.

02

Conditions studied

  • Urologic Diseases
  • Urological System Complication of Procedure

Browse trials for

Keywords

  • urology
  • ureteral stent
03

In context

Urologic Diseases

193 studies on the registry are indexed under Urologic Diseases; 51 are open to participants now.

Browse Urologic Diseases studies →

Lead sponsor

University of Louisville is the lead sponsor of 284 studies on the registry; 53 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Those undergoing ureteral stent placement for nephrolithiasis, hydronephrosis, and urological cancer.

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Intraureteral stent group

    Patients assigned to this group will undergo placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in only in the kidney and NOT in the bladder. This group will be the experimental group.

    Device: Intraureteral stent

  • Active comparator
    Conventional Double-J stent

    Patients assigned to this group will undergo placement of a double-J ureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and the bladder. This group will serve as the control.

    Device: Conventional Double-J stent

Interventions

  • DeviceIntraureteral stent

    This intervention involves the placement of an intraureteral stent, a tube that drains urine from the kidney to the bladder and has a loop of tube only in the kidney and NOT in the bladder. The distal end of the tube will stay in the ureter just proximal to the opening to the bladder.

    Also known as: Polaris™ Loop Ureteral Stent - Boston Scientific

  • DeviceConventional Double-J stent

    This intervention involves the placement of a conventional double-J stent, a tube that drains urine from the kidney to the bladder and has a loop of tube in both the kidney and in the bladder.

06

What researchers measure

Primary outcomes

  1. Stent migration

    The distance that the stent migrates into the bladder or into the kidney.

    Time frame: 12 months

Secondary outcomes

  1. Patient comfort level

    Patient comfort level, as assessed via the Ureteral stent symptom questionnaire (USSQ).

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Finney RP. Experience with new double J ureteral catheter stent. 1978. J Urol. 2002 Feb;167(2 Pt 2):1135-8; discussion 1139. doi: 10.1016/s0022-5347(02)80361-5. No abstract available. PubMed 11905888 ↗
  • Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002 Apr;59(4):511-6. doi: 10.1016/s0090-4295(01)01644-2. PubMed 11927301 ↗
  • Pollard SG, Macfarlane R. Symptoms arising from Double-J ureteral stents. J Urol. 1988 Jan;139(1):37-8. doi: 10.1016/s0022-5347(17)42282-8. PubMed 2961892 ↗
  • Yoshida T, Inoue T, Taguchi M, Matsuzaki T, Murota T, Kinoshita H, Matsuda T. Efficacy and Safety of Complete Intraureteral Stent Placement versus Conventional Stent Placement in Relieving Ureteral Stent Related Symptoms: A Randomized, Prospective, Single Blind, Multicenter Clinical Trial. J Urol. 2019 Jul;202(1):164-170. doi: 10.1097/JU.0000000000000196. Epub 2019 Jun 7. PubMed 30829132 ↗
  • Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003 Mar;169(3):1060-4. doi: 10.1097/01.ju.0000049198.53424.1d. PubMed 12576846 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04763837
Lead sponsor
University of Louisville
Responsible party
Kellen Choi (Asst Professor, University of Louisville) — Principal investigator
First posted
Feb 21, 2021
Start date
Feb 2027 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Apr 29, 2022

Study contacts

Kellen B Choi, DO, FACOS
principal investigator · Associate Professor, University of Louisville Department of Urology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion